Icure Pharma Amends Paid-in Capital Increase Details
아이큐어
175250
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2692
Risk-adjusted indicator based on 2692 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Previous Payment Date: August 6, 2026
- • Amended Payment Date: August 19, 2026
- • Previous Listing Date: August 20, 2026
- • Amended Listing Date: September 2, 2026
- • Max Shareholder Change: Choi Young-kwon (13.6%) to SoluM Cosmetic Co., Ltd. (35.31%)
AI Analysis Summary
Icure Pharmaceutical has amended its Material Fact Report regarding a paid-in capital increase. Key changes include shifting the payment date from August 6, 2026, to August 19, 2026, and the new share listing date from August 20, 2026, to September 2, 2026. The capital increase is intended to normalize accounts receivable and payable, recover operating cash flow, and resolve financial uncertainties stemming from a past embezzlement case, including an 8B KRW withholding tax payment. This move is expected to stabilize governance and management. The maximum shareholder is projected to change from Choi Young-kwon (13.6%) to SoluM Cosmetic Co., Ltd. (35.31%) upon completion of the capital increase. The new shares will be subject to a 1-year mandatory lock-up, with 70% (14,352,031 shares) subject to a further 1-year transfer restriction.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.